⟵ Back to Search Results

AdvanTIG-204

Active, not recruiting

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Beigene Study ID info

AdvanTIG-204

ClinicalTrials.gov ID info

NCT04952597

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents